BioHiTech to Conduct Live Product Demonstrations of Altapure High-Level Disinfectant Technology for Use Against Bacteria and Viruses such as Coronavirus 2 (SARS-CoV-2) with Potential Customers Starting in June
CHESTNUT RIDGE, N.Y., June 15, 2020 /PRNewswire/ -- BioHiTech Global, Inc. ("BioHiTech" or the "Company") (NASDAQ: BHTG), a technology and services company that provides cost-effective and sustainable environmental management solutions, today provided an update on the progress of its new, high-level disinfectant distribution business.
After entering into a distribution agreement in May, the Company has had preliminary discussions with potential customers in the healthcare, hospitality and education markets that have led to the scheduling of live product demonstrations of the Altapure AP-4(TM), beginning in June. While it has not yet received any purchase orders, the Company is encouraged by the initial level of interest and the potential opportunities that are being discussed.
"We are excited about the initial interest we have seen from several potential customers in making the AP-4 a part of their post-COVID safety and disinfecting initiatives," said Frank E. Celli, CEO of BioHiTech. "We are looking forward to demonstrating the environmentally sound, high-level disinfection capabilities of the AP-4 in an actual customer setting so that target customers can evaluate its ability to keep areas such as infirmaries, guest or patient rooms, classrooms, and small common areas properly disinfected in a post-COVID-19 environment."
The Altapure AP-4 is an enhanced, automated and touchless high-level disinfection sub-micron aerosol system launched in 2017, providing a safe process and rapid kill of spores, viruses, and vegetative bacteria, such as but not limited to: COVID-19, Acinetobacter baumannii, Pseudomonas aeruginosa, VRE, MRSA, Bacillus atrophaeus, Geobacillus stearothermophilus, Polio virus, C. auris and Clostridium difficile (C. difficile). Extensive research and development alongside Harris Corporation, formerly ITT Exelis, a top-tier global aerospace, defense, and information solutions company, resulted in the creation of a very unique and patented aerosol generation technology that when coupled with the liquid agent Altacare(®), a reagent grade peracetic acid solution, yields rapid and unparalleled results for high level disinfection. Altapure is committed to providing its customers with the highest quality products and processes in the marketplace that are safe to use and are environmentally friendly. All of Altapure's products are engineered, manufactured, and assembled in the U.S.
About BioHiTech Global
BioHiTech Global, Inc. (NASDAQ: BHTG), is changing the way we think about managing waste. Our cost-effective technology solutions include the patented processing of municipal solid waste into a valuable renewable fuel, biological disposal of food waste on-site, and proprietary real-time data analytics tools to reduce food waste generation. Our unique solutions enable businesses and municipalities of all sizes to lower disposal costs while having a positive impact on the environment. When used individually or in combination, our solutions lower the carbon footprint associated with waste transportation and can reduce or virtually eliminate landfill usage. For more information, please visit www.biohitech.com.
Forward Looking Statements
Statements in this press release contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. Without limiting the foregoing, words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "explore," "evaluate," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," or "will," or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These statements are also based on many assumptions and estimates and are not guarantees of future performance. These statements are estimates, based on information available to management as of the date of this release, and are subject to further changes. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of BioHiTech Global, Inc. to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. BioHiTech Global, Inc. assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission ("SEC"). There may be other factors not mentioned above or included in the BioHiTech's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. BioHiTech Global, Inc. assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.
Company Contact:
BioHiTech Global, Inc.
Richard Galterio
Executive Vice President
Direct: 845.367.0603
rgalterio@biohitech.com
www.biohitech.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/biohitech-to-conduct-live-product-demonstrations-of-altapure-high-level-disinfectant-technology-for-use-against-bacteria-and-viruses-such-as-coronavirus-2-sars-cov-2-with-potential-customers-starting-in-june-301076658.html
SOURCE BioHiTech Global, Inc.
